XV Eurasian Hematology-Oncology Congress - EHOC 2024

 

XV Eurasian Hematology-Oncology Congress - EHOC 2024
Avatar

Novel Agents in the Treatment of R/R CLL

By XV Eurasian Hematology-Oncology Congress - EHOC 2024 FEATURING Nitin Jain
By XV Eurasian Hematology-Oncology Congress - EHOC 2024 FEATURING Nitin Jain
44 views
October 9, 2024

Chapters

Decade of CLL Target Therapy & Recent Approvals

00:00

Treatment Sequencing Scenarios in CLL

01:38

Transition from Ibrutinib to Second-Gen BTK Inhibitors

03:54

Pirtobrutinib Approval & Resistance Challenges

05:51

CAR-T Liso-cel Approval & PFS Analysis

10:21

Emerging CLL Therapies & BTK Degraders

12:17

Comments 0
Login to view comments. Click here to Login
Leukemia
22:08

Pediatric ALL: Etiology, Diagnosis and Management

XV Eurasian Hematology-Oncology Congress - EHOC 2024

O. TüFekçI GüRocak

23 views
23:50

CML Case Discussion: Elderly Patients not Meeting ELN Milestones

XV Eurasian Hematology-Oncology Congress - EHOC 2024

M. Isam Sharif

9 views
15:42

CLL Case: Acquired Del(17p) at Relapse

XV Eurasian Hematology-Oncology Congress - EHOC 2024

M. Özer Çerme

8 views
03:40

ALL Case: B-ALL Arising During Len Maintenance in Myeloma Patient

XV Eurasian Hematology-Oncology Congress - EHOC 2024

K. Ozsoy

15:34

Novel Agents in the Treatment of R/R CLL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Jain

44 views
17:52

Venetoclax-Based Regimens in AML: Understanding Resistance and Devel…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Daver

120 views
16:58

Targeted Therapies in AML With a Focus on FLT3 Inhibitors

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Daver

38 views
22:58

A Clinical Case of Extranodal MZL of the Palatum Durum After CLL/SLL…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Ridova

9 views
12:18

Debates in CLL: Continuous or Finite Duration Therapy

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Jain

165 views
17:45

Ph+ ALL Management: Case-Based Discussion

XV Eurasian Hematology-Oncology Congress - EHOC 2024

K. Koruk

20 views
17:37

AML Case Discussion: FLT3-ITD+ High-Risk Disease

XV Eurasian Hematology-Oncology Congress - EHOC 2024

F. Hindilerden

25 views
18:32

Immunotherapy and Sequencing CD19-Targeted Therapies in Adults With …

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Jabbour

42 views
15:51

How I Treat R/R CML in 2024: Strategies and Emerging Therapies

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Jabbour

26 views
20:29

TKI Discontinuation in CML: Defining Eligibility Criteria and Predic…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

M. Yassin

29 views
07:49

A Case of CMML With Recurrent Skin Involvement

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Arslan Davulcu

13 views
15:14

Critical Re-Evaluation of Established Practices in CML Management

XV Eurasian Hematology-Oncology Congress - EHOC 2024

H. Kantarjian

173 views
28:43

Management of R/R AML: Treatment Options and Case Insights

XV Eurasian Hematology-Oncology Congress - EHOC 2024

V. Bonuomo

42 views
19:01

Debates in AML: 7+3 Is No Longer the Standard of Care

XV Eurasian Hematology-Oncology Congress - EHOC 2024

T. Kadia

727 views
14:17

Practical Approach to MRD Monitoring in AML: Assessing Treatment Eff…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

T. Kadia

108 views
10:30

Debates in Ph+ ALL: Allo-SCT Should Be Used Upfront in Adult Patients

XV Eurasian Hematology-Oncology Congress - EHOC 2024

D. Hoelzer

31 views
09:06

Debates in Ph+ ALL: Allo-SCT Is Not Necessary Upfront in Adult Patie…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Jabbour

43 views
23:52

CLL Case Discussion: First Line Treatment Strategies

XV Eurasian Hematology-Oncology Congress - EHOC 2024

D. Ortaboz

60 views
18:01

Incorporation of Targeted and Immunotherapies in ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

H. Kantarjian

230 views
18:49

CAR-T in R/R ALL: Case-Based Discussion of Lymphodepletion and Toxic…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Erdogan

15 views
17:13

The Importance of MRD in ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

F. Ravandi

183 views
22:26

Management of AML in Older Patients

XV Eurasian Hematology-Oncology Congress - EHOC 2024

F. Ravandi

204 views
34:29

Current Approaches to Managing T-Cell ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

A. Ibrahim

23 views
15:10

TKI Toxicity Management in CML: A Case-Based Discussion

XV Eurasian Hematology-Oncology Congress - EHOC 2024

A. Alshurafa

20 views
18:56

Management of Persistently MRD+ ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

A. Odabasi Giden

36 views
18:07

Debates in AML: 3+7 is the SOC Induction Therapy for AML

XV Eurasian Hematology-Oncology Congress - EHOC 2024

A. Uzay

58 views
11:33

Venetoclax + Ibrutinib as 1L Treatment in Patients With CLL: Meta-An…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

A. Sarici

31 views
16:19

Current Options for Finite-Duration Therapy With BTKis in CLL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

A. Ibrahim

149 views